NCT01991379 2025-12-04
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
NCT03106415 2025-06-27
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase 1/2 Completed
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT04720768 2024-01-05
CELEBRATE
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed
NCT02773459 2019-09-30
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 1/2 Completed